NanoSphere Health Sciences Inc. (NSHSF)
USD 0.04
(-60.0%)
USD 0.04
(-60.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 220.07 Thousand USD | -22.47% |
| 2022 | 283.87 Thousand USD | -26.46% |
| 2021 | 386 Thousand USD | -31.76% |
| 2020 | 565.62 Thousand USD | -83.66% |
| 2019 | 3.46 Million USD | -25.38% |
| 2018 | 4.63 Million USD | 322.31% |
| 2017 | 1.09 Million USD | 76.6% |
| 2016 | 621.86 Thousand USD | 436.32% |
| 2015 | 115.95 Thousand USD | -34.98% |
| 2014 | 178.33 Thousand USD | -83.64% |
| 2013 | 1.08 Million USD | -57.72% |
| 2012 | 2.57 Million USD | -17.05% |
| 2011 | 3.1 Million USD | 1471.59% |
| 2010 | 197.71 Thousand USD | 27.82% |
| 2009 | 154.68 Thousand USD | -54.57% |
| 2008 | 340.52 Thousand USD | -70.72% |
| 2007 | 1.16 Million USD | 2754.71% |
| 2006 | 40.74 Thousand USD | 41.24% |
| 2005 | 28.84 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 31.86 Thousand USD | -51.06% |
| 2024 Q2 | 56.7 Thousand USD | 63.37% |
| 2023 FY | 241.13 Thousand USD | -15.06% |
| 2023 Q3 | 52.67 Thousand USD | -21.41% |
| 2023 Q4 | 65.11 Thousand USD | 23.63% |
| 2023 Q1 | 53.73 Thousand USD | -53.88% |
| 2023 Q2 | 67.02 Thousand USD | 24.73% |
| 2022 Q3 | 18.33 Thousand USD | -75.85% |
| 2022 FY | 283.87 Thousand USD | -26.46% |
| 2022 Q2 | 75.94 Thousand USD | 3.91% |
| 2022 Q1 | 73.08 Thousand USD | -17.33% |
| 2022 Q4 | 116.51 Thousand USD | 535.46% |
| 2021 Q1 | 69.79 Thousand USD | -55.01% |
| 2021 Q2 | 145.9 Thousand USD | 109.05% |
| 2021 Q3 | 81.91 Thousand USD | -43.86% |
| 2021 FY | 386 Thousand USD | -31.76% |
| 2021 Q4 | 88.39 Thousand USD | 7.92% |
| 2020 FY | 565.62 Thousand USD | -83.66% |
| 2020 Q1 | 226.63 Thousand USD | -78.8% |
| 2020 Q2 | 115.69 Thousand USD | -48.95% |
| 2020 Q3 | 68.15 Thousand USD | -41.09% |
| 2020 Q4 | 155.13 Thousand USD | 127.62% |
| 2019 Q2 | 525.09 Thousand USD | -47.74% |
| 2019 Q4 | 1.06 Million USD | 23.95% |
| 2019 FY | 3.46 Million USD | -25.38% |
| 2019 Q1 | 1 Million USD | -34.92% |
| 2019 Q3 | 862.34 Thousand USD | 64.23% |
| 2018 FY | 4.63 Million USD | 322.31% |
| 2018 Q1 | 998.12 Thousand USD | 25.7% |
| 2018 Q4 | 1.54 Million USD | 42.78% |
| 2018 Q3 | 1.08 Million USD | 6.55% |
| 2018 Q2 | 1.01 Million USD | 1.67% |
| 2017 FY | 1.09 Million USD | 76.6% |
| 2017 Q4 | 794.06 Thousand USD | 794.33% |
| 2017 Q2 | 129.85 Thousand USD | 76.15% |
| 2017 Q1 | 73.72 Thousand USD | -12.29% |
| 2017 Q3 | 88.78 Thousand USD | -31.63% |
| 2016 Q3 | 464.73 Thousand USD | 836.9% |
| 2016 FY | 621.86 Thousand USD | 436.32% |
| 2016 Q1 | 24.58 Thousand USD | 2.5% |
| 2016 Q4 | 84.05 Thousand USD | -81.91% |
| 2016 Q2 | 49.6 Thousand USD | 101.75% |
| 2015 Q4 | 23.98 Thousand USD | 2.6% |
| 2015 Q3 | 23.37 Thousand USD | -42.06% |
| 2015 Q1 | 33.11 Thousand USD | 118.76% |
| 2015 Q2 | 40.35 Thousand USD | 21.83% |
| 2015 FY | 115.95 Thousand USD | -34.98% |
| 2014 FY | 178.33 Thousand USD | -83.64% |
| 2014 Q2 | 64.42 Thousand USD | 13.38% |
| 2014 Q1 | 56.81 Thousand USD | -73.75% |
| 2014 Q4 | -176.56 Thousand USD | -174.48% |
| 2014 Q3 | 237.05 Thousand USD | 267.96% |
| 2013 Q4 | 216.42 Thousand USD | 27.48% |
| 2013 Q3 | 169.76 Thousand USD | -53.97% |
| 2013 Q2 | 368.83 Thousand USD | 11.09% |
| 2013 Q1 | 332.01 Thousand USD | -42.57% |
| 2013 FY | 1.08 Million USD | -57.72% |
| 2012 Q4 | 578.07 Thousand USD | -3.19% |
| 2012 FY | 2.57 Million USD | -17.05% |
| 2012 Q2 | 823.17 Thousand USD | 51.26% |
| 2012 Q3 | 597.12 Thousand USD | -27.46% |
| 2012 Q1 | 544.19 Thousand USD | -28.54% |
| 2011 FY | 3.1 Million USD | 1471.59% |
| 2011 Q4 | 761.55 Thousand USD | 24.63% |
| 2011 Q1 | 1.04 Million USD | 1256.59% |
| 2011 Q2 | 812.33 Thousand USD | -22.33% |
| 2011 Q3 | 611.06 Thousand USD | -24.78% |
| 2010 FY | 197.71 Thousand USD | 27.82% |
| 2010 Q3 | 48.78 Thousand USD | 26.02% |
| 2010 Q2 | 38.71 Thousand USD | 18.49% |
| 2010 Q1 | 32.67 Thousand USD | 5.04% |
| 2010 Q4 | 77.1 Thousand USD | 58.04% |
| 2009 Q3 | 32.41 Thousand USD | -25.11% |
| 2009 FY | 154.68 Thousand USD | -54.57% |
| 2009 Q4 | 31.1 Thousand USD | -4.05% |
| 2009 Q2 | 43.28 Thousand USD | 15.8% |
| 2009 Q1 | 37.37 Thousand USD | 100.61% |
| 2008 FY | 340.52 Thousand USD | -70.72% |
| 2008 Q4 | -6.16 Million USD | -198.51% |
| 2008 Q3 | 6.26 Million USD | 4442.23% |
| 2008 Q2 | 137.83 Thousand USD | 17.92% |
| 2008 Q1 | 116.88 Thousand USD | -84.9% |
| 2007 Q4 | 774.26 Thousand USD | 165.98% |
| 2007 Q1 | 4444.35 USD | -73.63% |
| 2007 FY | 1.16 Million USD | 2754.71% |
| 2007 Q2 | 84.34 Thousand USD | 1797.8% |
| 2007 Q3 | 291.09 Thousand USD | 245.13% |
| 2006 Q2 | 6296.00 USD | -45.2% |
| 2006 Q4 | 16.85 Thousand USD | 200.68% |
| 2006 Q3 | 5606.30 USD | -10.95% |
| 2006 FY | 40.74 Thousand USD | 41.24% |
| 2006 Q1 | 11.48 Thousand USD | 81.67% |
| 2005 FY | 28.84 Thousand USD | 0.0% |
| 2005 Q3 | 22.27 Thousand USD | 0.0% |
| 2005 Q4 | 6323.53 USD | -71.61% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 83.52% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 95.635% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.255% |
| Nascent Biotech, Inc. | 2.22 Million USD | 90.13% |
| Rebus Holdings, Inc. | 664 Thousand USD | 66.856% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.409% |
| Qrons Inc. | 643.67 Thousand USD | 65.809% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 43.507% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.617% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 47.03% |
| Skye Bioscience, Inc. | 13.54 Million USD | 98.376% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.746% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 95.525% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 15.913% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.743% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 92.453% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 85.347% |
| Mesoblast Limited | 5.9 Million USD | 96.271% |
| Marizyme, Inc. | 19.23 Million USD | 98.856% |
| Genus plc | 147.7 Million USD | 99.851% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 97.493% |
| Pharming Group N.V. | 225.49 Million USD | 99.902% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 89.258% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 83.595% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 97.361% |
| ContraFect Corporation | 56.88 Million USD | 99.613% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 95.008% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 85.117% |
| IMV Inc. | 37.7 Million USD | 99.416% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 92.113% |
| MultiCell Technologies, Inc. | 567.42 USD | -38685.732% |
| ONE Bio Corp. | 6.44 Million USD | 96.585% |
| Accustem Sciences Inc. | 3.74 Million USD | 94.126% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.744% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 58.629% |
| Q BioMed Inc. | 3.43 Million USD | 93.596% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.11% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 91.624% |
| Biomind Labs Inc. | 994.18 Thousand USD | 77.863% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.778% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 87.493% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 96.724% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 88.196% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 980.312% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 98.625% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 88.007% |
| GB Sciences, Inc. | 1.42 Million USD | 84.507% |
| Alpha Cognition Inc. | 9.7 Million USD | 97.732% |
| HST Global, Inc. | 140.9 Thousand USD | -56.187% |
| CSL Limited | 3.44 Billion USD | 99.994% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 80.436% |
| Halberd Corporation | 74.84 Thousand USD | -194.057% |
| Enzolytics Inc. | 2.17 Million USD | 89.902% |
| Agentix Corp. | 1.37 Million USD | 83.956% |
| Resverlogix Corp. | 12.71 Million USD | 98.269% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 93.972% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.986% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 78.92% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 90.849% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 86.065% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 93.537% |
| AVAX Technologies, Inc. | 7.31 Million USD | 96.989% |
| Zenith Capital Corp. | 8.94 Million USD | 97.539% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.973% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1163.291% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 91.037% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -28.319% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 88.543% |
| Kadimastem Ltd | 2.41 Million USD | 90.869% |
| Helix BioMedix, Inc. | 1.97 Million USD | 88.84% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 97.975% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.042% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -21.265% |
| LadRx Corporation | 3.81 Million USD | 94.226% |
| Cell Source, Inc. | 4.32 Million USD | 94.912% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 76.169% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 76.169% |
| NovAccess Global Inc. | 2.46 Million USD | 91.078% |
| Affymax, Inc. | 39.38 Million USD | 99.441% |
| Itoco Inc. | 919.14 Thousand USD | 76.056% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 94.808% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 80.333% |
| Mobile Lads Corp. | 554.54 Thousand USD | 60.314% |
| CytoDyn Inc. | 18.05 Million USD | 98.781% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -774.401% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 84.499% |
| SYBLEU INC | 160.87 Thousand USD | -36.8% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 87.883% |
| International Stem Cell Corporation | 5.27 Million USD | 95.825% |
| Bioxytran, Inc. | 3.82 Million USD | 94.239% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -318.065% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -981.837% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.393% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 86.398% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 70.091% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 92.926% |
| Neutra Corp. | 243.82 Thousand USD | 9.738% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 98.739% |
| PureTech Health plc | 144.59 Million USD | 99.848% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 98.926% |
| IXICO plc | 4.7 Million USD | 95.324% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 97.498% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.813% |
| CSL Limited | 3.89 Billion USD | 99.994% |
| Cellectis S.A. | 97.32 Million USD | 99.774% |